EssilorLuxottica (EL) | Financial Analysis & Statements
EssilorLuxottica S.A. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
63.9B
Total Liabilities
24.4B
Shareholders Equity
39.5B
Debt to Equity
0.62
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2025
EssilorLuxottica Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 28.5B | 26.5B | 25.4B | 24.5B | 19.8B |
| Cost of Goods Sold | 11.2B | 9.7B | 9.3B | 8.9B | 7.6B |
| Gross Profit | 17.3B | 16.8B | 16.0B | 15.6B | 12.2B |
| Gross Margin % | 60.6% | 63.4% | 63.2% | 63.6% | 61.7% |
| Operating Expenses | |||||
| Research & Development | 664.0M | 630.0M | 593.0M | 600.0M | 579.0M |
| Selling, General & Administrative | 13.0B | 12.5B | 12.1B | 11.7B | 9.2B |
| Other Operating Expenses | 249.0M | 252.0M | 246.0M | 219.0M | 174.0M |
| Total Operating Expenses | 13.9B | 13.4B | 12.9B | 12.5B | 10.0B |
| Operating Income | 3.4B | 3.4B | 3.2B | 3.2B | 2.2B |
| Operating Margin % | 11.9% | 13.0% | 12.5% | 12.9% | 11.3% |
| Non-Operating Items | |||||
| Interest Income | 85.0M | 92.0M | 85.0M | 26.0M | 30.0M |
| Interest Expense | 314.0M | 253.0M | 198.0M | 156.0M | 141.0M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 3.2B | 3.3B | 3.0B | 3.0B | 2.2B |
| Income Tax | 752.0M | 800.0M | 609.0M | 751.0M | 582.0M |
| Effective Tax Rate % | 23.5% | 24.3% | 20.1% | 24.8% | 26.7% |
| Net Income | 2.4B | 2.5B | 2.4B | 2.3B | 1.6B |
| Net Margin % | 8.6% | 9.4% | 9.6% | 9.3% | 8.1% |
| Key Metrics | |||||
| EBITDA | 6.6B | 6.6B | 6.2B | 6.1B | 4.7B |
| EPS (Basic) | €5.04 | €5.20 | €5.11 | €4.87 | €3.23 |
| EPS (Diluted) | €4.98 | €5.13 | €5.08 | €4.83 | €3.18 |
| Basic Shares Outstanding | 459018876 | 453926761 | 448066944 | 442049822 | 448439100 |
| Diluted Shares Outstanding | 459018876 | 453926761 | 448066944 | 442049822 | 448439100 |
Income Statement Trend
EssilorLuxottica Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 3.5B | 2.3B | 2.6B | 2.0B | 3.3B |
| Short-term Investments | - | - | 1.0M | - | - |
| Accounts Receivable | 3.6B | 3.3B | 2.9B | 2.7B | 2.4B |
| Inventory | 3.5B | 3.2B | 2.8B | 2.8B | 2.4B |
| Other Current Assets | 298.0M | 331.0M | 525.0M | 258.0M | 212.0M |
| Total Current Assets | 12.0B | 10.0B | 9.7B | 8.6B | 9.3B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 5.2B | 5.0B | 7.0B | 2.4B | 2.2B |
| Goodwill | 71.8B | 75.1B | 71.5B | 73.6B | 70.8B |
| Intangible Assets | 9.8B | 11.0B | 11.0B | 12.1B | 12.6B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 539.0M | 603.0M | 306.0M | 817.0M | 111.0M |
| Total Non-Current Assets | 51.9B | 54.2B | 50.8B | 51.9B | 50.1B |
| Total Assets | 63.9B | 64.3B | 60.5B | 60.6B | 59.4B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 2.9B | 2.7B | 2.4B | 2.3B | 2.2B |
| Short-term Debt | 3.7B | 1.9B | 1.4B | 1.0B | 1.6B |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.6B | 1.6B | 1.5B | 1.4B | 1.3B |
| Total Current Liabilities | 10.9B | 9.1B | 8.4B | 7.9B | 8.7B |
| Non-Current Liabilities | |||||
| Long-term Debt | 10.7B | 11.3B | 10.3B | 11.2B | 11.4B |
| Deferred Tax Liabilities | 1.9B | 2.0B | 2.1B | 2.4B | 2.5B |
| Other Non-Current Liabilities | 34.0M | 26.0M | 36.0M | 43.0M | 47.0M |
| Total Non-Current Liabilities | 13.5B | 14.2B | 13.2B | 14.5B | 14.9B |
| Total Liabilities | 24.4B | 23.3B | 21.6B | 22.4B | 23.5B |
| Equity | |||||
| Common Stock | 83.0M | 82.0M | 82.0M | 81.0M | 80.0M |
| Retained Earnings | 2.3B | 2.4B | 2.3B | 2.2B | 1.4B |
| Treasury Stock | 25.0M | 172.0M | 312.0M | 360.0M | 231.0M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 39.5B | 41.0B | 38.9B | 38.1B | 35.9B |
| Key Metrics | |||||
| Total Debt | 14.4B | 13.2B | 11.7B | 12.2B | 13.0B |
| Working Capital | 1.1B | 966.0M | 1.3B | 752.0M | 602.0M |
Balance Sheet Composition
EssilorLuxottica Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 2.4B | 2.5B | 2.4B | 2.3B | 1.6B |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 280.0M | 162.0M | 195.0M | 191.0M | 160.0M |
| Working Capital Changes | -446.0M | -607.0M | -459.0M | -356.0M | 132.0M |
| Operating Cash Flow | 2.4B | 2.2B | 2.3B | 2.2B | 2.0B |
| Investing Activities | |||||
| Capital Expenditures | -1.5B | -1.5B | -1.5B | -1.6B | -1.0B |
| Acquisitions | -911.0M | -1.8B | -114.0M | -965.0M | -7.1B |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -2.4B | -3.3B | -1.6B | -2.5B | -8.1B |
| Financing Activities | |||||
| Share Repurchases | -376.0M | -274.0M | -271.0M | -431.0M | -317.0M |
| Dividends Paid | -547.0M | -1.2B | -487.0M | -454.0M | -138.0M |
| Debt Issuance | 992.0M | 2.0B | 0 | 0 | 57.0M |
| Debt Repayment | -2.5B | -2.2B | -2.0B | -1.4B | -800.0M |
| Financing Cash Flow | 556.0M | -1.2B | -1.9B | -3.9B | -1.2B |
| Free Cash Flow | 3.8B | 3.4B | 3.3B | 3.2B | 3.5B |
| Net Change in Cash | 579.0M | -2.2B | -1.2B | -4.3B | -7.3B |
Cash Flow Trend
EssilorLuxottica Key Financial Ratios
No financial ratio data available.
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| Sartorius Stedim | 15.8B | 59.45 | 3.86 | 6.59% | 8.98% | 63.11 |
| Crossject S.A | 105.6M | - | - | 212.74% | 0.00% | -4.61 |
| Visiomed Group SA | 52.8M | 59.67 | - | 3.64% | 45.95% | 0.32 |
| Spineway S.A | 5.8M | 16.20 | 0.25 | -9.46% | -17.47% | 6.63 |
Financial data is updated regularly. All figures are in the company's reporting currency.